Protease-activated receptors as targets for antiplatelet therapy

scientific article published on 21 July 2008

Protease-activated receptors as targets for antiplatelet therapy is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1016/J.BLRE.2008.06.002
P698PubMed publication ID18644663
P5875ResearchGate publication ID51418610

P2093author name stringJustin R Hamilton
P433issue2
P304page(s)61-65
P577publication date2008-07-21
P1433published inBlood ReviewsQ15724415
P1476titleProtease-activated receptors as targets for antiplatelet therapy
P478volume23

Reverse relations

cites work (P2860)
Q42951363Differential effects of quercetin, apigenin and genistein on signalling pathways of protease-activated receptors PAR(1) and PAR(4) in platelets.
Q33580620Differential signaling by protease-activated receptors: implications for therapeutic targeting.
Q34255442Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease
Q51522575Inhibition of protease-activated receptor 4 impairs platelet procoagulant activity during thrombus formation in human blood.
Q38123237Investigational anticoagulants for hematological conditions: a new generation of therapies.
Q33902628Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor
Q41960992Personalized healthcare in clotting disorders
Q90133870Platelet P-selectin triggers rapid surface exposure of tissue factor in monocytes
Q50002204Protease-Activated Receptor 4 (PAR4): A Promising Target for Antiplatelet Therapy.
Q58727906Rapid kinetics of changes in oxygen consumption rate in thrombin-stimulated platelets measured by high-resolution respirometry
Q36110533Safety and efficacy of targeting platelet proteinase-activated receptors in combination with existing anti-platelet drugs as antithrombotics in mice
Q37687166Synthesis of N-arylmethyl Substituted Indole Derivatives as New Antiplatelet Aggregation Agents
Q42920627The anti-platelet effects of apocynin in mice are not mediated by inhibition of NADPH oxidase activity
Q38800853The pharmacodynamics of antiplatelet compounds in thrombosis treatment
Q28246124Thrombin and vascular inflammation
Q28281696Thrombin receptors and their antagonists: an update on the patent literature

Search more.